This technology selected novel Ex-50.T aptamers by using the most aggressive subtypes of breast cancer (triple-negative and HER2) and the results showed that Ex-50.T aptamers were the functional inhibitor of exosome cellular uptake and antagonizes cancer exosome-induced cell migration in vitro. Here, ERBB2 is linked to cancer.